The Complete Nootropics Masterclass Volume 8 — Public Appendices & Reference Tools

[enchanted_elixir]

THE COMPLETE NOOTROPICS MASTERCLASS
VOLUME 8: PUBLIC APPENDICES
REFERENCE TABLES • TRIAL TEMPLATES • GLOSSARY • SOURCING • INDEX​

---

Compiled with AI assistance from the finished masterclass and edited as a public reference companion.​

Spoiler: Appendix A — Pharmacology Reference Terms

Appendix A — Pharmacology Reference Terms​

Term	Practical meaning
Kd	Equilibrium dissociation constant: the concentration at which roughly half the available receptors are occupied in a simple binding system. Lower often means higher affinity.
Ki	Inhibition constant estimated from a competition assay. It describes binding under those assay conditions—not a human dose.
EC50	Concentration producing half of the compound's maximum measured effect in that experiment.
IC50	Concentration producing half-maximal inhibition in that experiment; assay conditions strongly affect it.
ED50	Dose producing a defined effect in half a population, or half-maximal effect depending on context. Always check the study's definition.
Efficacy	Maximum response a compound can produce in the measured system.
Potency	Amount or concentration required for a given response. Greater potency does not mean greater benefit.
Affinity	Tendency to bind a target. Binding alone does not establish activation, useful selectivity in the body, or clinical value.
Selectivity	Preference for one target over others across a stated concentration range. Selectivity can disappear as exposure rises.
Bioavailability	Fraction of an administered dose reaching systemic circulation unchanged.
Cmax / Tmax	Highest measured concentration and the time at which it occurs.
Clearance	Volume of biological fluid cleared of drug per unit time; it combines the relevant elimination processes.
Half-life	Time for concentration to fall by half during the stated phase. It does not by itself determine complete washout.
Volume of distribution	Apparent volume relating the amount in the body to the measured plasma concentration; it is not a literal anatomical container.
Steady state	Repeated-dose condition in which average input and elimination balance, commonly approached after several half-lives.
AUC	Area under the concentration–time curve, representing total measured exposure.
Therapeutic window	Exposure range between useful effect and unacceptable toxicity.
Active metabolite	Metabolic product that contributes pharmacological effects and may outlast the parent compound.
Agonist / antagonist	An agonist activates a receptor; an antagonist blocks activation without necessarily producing the opposite intracellular signal.
Partial agonist	Activates a receptor but produces a lower maximum response than a full agonist in the same system.
PAM / NAM	Positive or negative allosteric modulator; changes receptor response through a site distinct from the primary ligand site.

Spoiler: Appendix B — Major Neurotransmitter Systems

Appendix B — Major Neurotransmitter Systems​

System	Major functions	Intervention points	Common overshoot
Acetylcholine	Attention, encoding, sensory selection, autonomic function, muscle activation	Choline supply, acetylcholinesterase, nicotinic and muscarinic receptors	Nausea, sweating, bradycardia, cramps, vivid dreams, confusion
Dopamine	Reward prediction, effort, action selection, movement, learning	Precursors, synthesis, transporters, MAO, D1- and D2-family receptors	Insomnia, impulsivity, rigidity, compulsions, psychosis
Norepinephrine	Arousal, vigilance, uncertainty, signal-to-noise regulation	Synthesis, release, reuptake, alpha and beta receptors	Anxiety, tremor, hypertension, narrowed attention
Serotonin	Mood, patience, appetite, sleep, flexibility, sensory processing	Synthesis, transporters, MAO, and many 5-HT receptors	Agitation, sexual and gastrointestinal effects, serotonin toxicity
Glutamate	Fast excitation, plasticity, learning	AMPA, NMDA, metabotropic receptors, transport and co-agonist sites	Noise, anxiety, seizures, excitotoxicity
GABA	Inhibition, network stability, sleep, anxiety regulation	GABA-A, GABA-B, synthesis and reuptake	Sedation, amnesia, respiratory interactions, dependence
Histamine	Wakefulness, attention, appetite, immune signaling	H1 and H3 receptors	Insomnia—or sedation and cognitive slowing with H1 blockade
Adenosine	Sleep pressure, energy-state signaling, vascular effects	A1 and A2A receptors	Antagonism can produce anxiety, tremor, and sleep disruption
Endogenous opioids	Pain, reward, stress, social state	Mu, delta, kappa, and NOP receptors	Respiratory depression, dysphoria, dependence, reward disruption
Endocannabinoids	Stress, memory, appetite, pain, synaptic regulation	CB1/CB2, FAAH, MAGL	Memory impairment, anxiety, altered motivation, cardiovascular effects
Orexin	Wake stability, motivation, arousal integration	OX1 and OX2 receptors	Excess activation may impair sleep or increase autonomic arousal

Spoiler: Appendix C — Cytochrome P450 Interaction Reference

Appendix C — Cytochrome P450 Interaction Reference​

Cytochrome P450 enzymes metabolize many drugs, but they are only part of disposition. Transporters, conjugation enzymes, kidney clearance, and active metabolites also matter. Inhibition can raise substrate exposure quickly; induction usually develops and resolves over days. The clinical effect depends on how dependent the drug is on that pathway and how narrow its therapeutic window is.

Pathway	Relevant examples	Modifiers	Key caution
CYP1A2	Caffeine, clozapine, olanzapine, tizanidine	Fluvoxamine and ciprofloxacin inhibit; tobacco smoke induces	Stopping smoking can raise exposure even when the drug dose is unchanged
CYP2C9	Warfarin, phenytoin, selected NSAIDs	Fluconazole inhibits; rifampin induces	Bleeding or toxicity can emerge from an apparently unrelated addition
CYP2C19	Clopidogrel activation, some PPIs, diazepam, citalopram	Omeprazole/esomeprazole inhibit; genetic variation matters	Inhibition may raise some drugs while reducing activation of a prodrug
CYP2D6	Many antidepressants and antipsychotics, metoprolol, codeine activation	Bupropion, fluoxetine, and paroxetine inhibit; major genetic variation exists	Poor metabolism or inhibition can mimic a high dose; prodrug effects may fall
CYP3A4/5	Many benzodiazepines, statins, calcium-channel blockers, hormones, and other drugs	Clarithromycin and azoles inhibit; grapefruit affects intestinal CYP3A; rifampin induces	This pathway produces numerous high-consequence interactions
MAO-A/B	Monoamines rather than ordinary CYP substrates	Selegiline has dose-dependent selectivity; methylene blue has important MAO-A activity	Combining serotonergic or sympathomimetic agents can become dangerous
P-glycoprotein and other transporters	Digoxin and many CNS or anticancer drugs	Numerous drugs alter transport to varying degrees	Brain and blood exposure can change without a CYP interaction

This table is not an interaction checker. Verify the complete combination through a pharmacist or clinician, including temporary medicines, anesthesia, supplements, food, nicotine, and alcohol.

Spoiler: Appendix D — Common Laboratory Tests

Appendix D — Common Laboratory Tests​

Test or group	What it can help assess	Important limitations
CBC	Anemia, infection patterns, platelets	Abnormalities require cause-specific interpretation
CMP	Electrolytes, glucose, kidney-associated markers, liver-associated enzymes and proteins	Hydration, exercise, muscle, medications, and timing affect results
Creatinine/eGFR; cystatin C when appropriate	Kidney-filtration estimate	Creatine, muscle mass, diet, age, and assay assumptions affect estimates
ALT, AST, ALP, bilirubin	Patterns of liver or bile-duct injury	AST also comes from muscle; a normal panel does not exclude every liver problem
Fasting glucose and HbA1c	Current and longer-term glycemic status	Hemoglobin disorders, anemia, illness, and timing can distort interpretation
Lipid panel, non-HDL-C, ApoB, Lp(a)	Atherogenic-particle and metabolic risk	Risk depends on the complete clinical and inherited context
TSH, free T4; antibodies when indicated	Thyroid regulation	Illness, medication, pregnancy, and timing affect results
Ferritin, iron studies, CBC	Iron stores and iron-related anemia	Ferritin rises with inflammation; serum iron varies
Vitamin B12, methylmalonic acid when indicated	B12 adequacy	Serum B12 alone can be ambiguous
Folate	Folate status in context	Supplementation can mask aspects of B12 deficiency
25-hydroxyvitamin D	Vitamin D status	Targets and supplementation should reflect indication and risk
Magnesium	Severe systemic deficiency or excess	Serum magnesium poorly reflects every intracellular pool
hs-CRP	Nonspecific systemic inflammatory signal	Infection, obesity, exercise, and injury can raise it
Blood pressure and ECG	Hemodynamic and rhythm baseline	One office pressure or short tracing does not capture all variability
Hormonal tests	Specific endocrine questions	Time, sex, age, cycle, binding proteins, and medications are essential context

Testing should be selected with a question and a response plan. Repeating a surprising result under standardized conditions is often more useful than ordering a larger unsupervised panel.

Spoiler: Appendix E — Cognitive-Testing Methods

Appendix E — Cognitive-Testing Methods​

Domain	Example method	Primary output	Major confounds
Vigilance	Psychomotor vigilance task	Lapses and reaction-time distribution	Device latency, sleep, interruption, practice
Processing speed	Symbol–digit or substitution tasks	Correct responses within time	Motor speed, vision, familiarity
Working memory	Digit span, spatial span, n-back, complex span	Capacity or accuracy under manipulation	Strategy, practice, task-specific learning
Inhibitory control	Go/no-go, stop-signal, Stroop-like tasks	False alarms or stopping latency	Speed–accuracy tradeoff
Verbal learning	Repeated word-list learning with delayed recall	Learning slope, delayed recall, recognition	Language, alternate-form difficulty, sleep
Spatial memory	Location or pattern-recall tasks	Accuracy and delayed retention	Vision, device, strategy
Cognitive flexibility	Task switching or rule-shift tests	Switch cost and errors	Motor demands, comprehension
Real-world function	Prespecified work or study unit	Accurate completed output and later retention	Workload difficulty, external help, motivation

Use the same device, time window, instructions, and environment. Familiarize before baseline, select one primary outcome, and retain raw trials when possible so variability and speed–accuracy tradeoffs can be examined.

Spoiler: Appendix F — Nootropic Trial Template

Appendix F — Nootropic Trial Template​

N-OF-1 TRIAL

QUESTION
Target problem:
Primary outcome:
Minimum meaningful improvement:

RATIONALE
Suspected bottleneck:
Proposed mechanism:
Best human evidence:
Lower-risk alternatives considered:

SAFETY
Medication and supplement list reviewed:
Contraindications and interactions:
Baseline measurements or clinician monitoring:
Stop immediately if:
Maximum planned exposure and duration:

DESIGN
Baseline dates:
Intervention dates:
Washout:
Repeat or crossover:
Randomization or blinding method:
Variables held constant:

MEASURES
Primary:
Secondary:
Sleep and adverse effects:
Real-world output:

DECISION RULE
Continue only if:
Stop if:
Inconclusive if:

RESULT
All observations:
Confounders:
Benefit:
Cost:
Final decision and date:

Spoiler: Appendix G — Adverse-Effect Tracking Template

Appendix G — Adverse-Effect Tracking Template​

Date/time:
Compound, formulation, batch, route, and active amount:
Other substances and timing:
Food, hydration, sleep, exercise, illness, and unusual stress:

Symptom:
Onset after exposure:
Severity (0–10):
Duration:
Objective measurements:
Effect on function:
Action taken:
Resolved after stopping?:
Returned after re-exposure?:

Urgent warning signs checked:
- chest pain, fainting, severe rhythm or blood-pressure change
- seizure, severe headache, weakness, speech or vision change
- breathing difficulty, facial swelling, widespread blistering rash
- fever with agitation, rigidity, tremor, or clonus
- suicidality, psychosis, mania-like behavior, dangerous impulsivity
- jaundice, dark urine with weakness, or major bleeding
Clinician/poison-control contact and advice:
Decision about product:

Spoiler: Appendix H — Compound-Evaluation Worksheet

Appendix H — Compound-Evaluation Worksheet​

COMPOUND PROFILE

IDENTITY
Generic name, chemical name, aliases, salt, stereochemistry:
Category—nutrient, botanical, approved drug, or investigational compound:
Product, batch, manufacturer, and verification:

MECHANISM
Direct target:
Action—agonist, antagonist, inhibitor, substrate, or modulator:
Downstream biomarkers kept separate:
Plausible bottleneck addressed:

EVIDENCE
Cell:
Animal:
Human disease population:
Healthy-human cognition:
Replication and major negative findings:
Does the studied formulation match the available product?

EXPOSURE
Route and bioavailability:
Brain or target-tissue evidence:
Onset, Tmax, half-life, active metabolites, and clearance:
Food, CYP, transporter, and organ-function considerations:

BENEFIT
Primary measurable outcome:
Expected magnitude and duration:
Practical alternative:

RISK
Common effects:
Serious effects:
Dependence, withdrawal, and tolerance:
Contraindications and interactions:
Pregnancy, development, fertility, and long-term uncertainty:
Product-quality, sterility, endotoxin, and storage risk:

DECISION
Evidence grade:
Risk class:
Monitoring and stopping rules:
Include, research only, or exclude:

Spoiler: Appendix I — Evidence-Grading Framework

Appendix I — Evidence-Grading Framework​

Grade	Minimum interpretation
A — Established for the stated use	Multiple credible controlled human studies or strong clinical consensus, relevant population and formulation, meaningful outcomes, and sufficiently characterized safety
B — Promising human evidence	At least one credible controlled human signal with plausible target engagement, but limited replication, duration, population match, or magnitude
C — Preliminary human evidence	Small, open-label, observational, surrogate-endpoint, or condition-mismatched human evidence; conclusion remains highly uncertain
D — Preclinical only	Cell or animal evidence without adequate human exposure and outcome evidence
E — Mechanism or anecdote	Theoretical reasoning, vendor claims, uncontrolled personal reports, or unclear identity

Add independent dimensions rather than compressing everything into one letter:

• Population match: exact / related disease / healthy mismatch
• Outcome match: functional cognition / cognitive test / surrogate / molecular marker
• Product match: exact formulation / related formulation / unknown product
• Replication: independent / same group / unreplicated
• Safety maturity: long clinical use / bounded trial exposure / preclinical / unknown
• Bias risk: low / some concerns / high

An A grade for treating narcolepsy does not become an A grade for healthy-person memory. Evidence grades always require the stated claim.

Spoiler: Appendix J — Glossary

Appendix J — Glossary​

Blood-brain barrier: selective vascular interface regulating movement between blood and neural tissue.

Catecholamines: dopamine, norepinephrine, and epinephrine.

Cognition: processes including perception, attention, memory, language, decision-making, learning, and control.

Excitotoxicity: cellular injury caused by pathological excitatory signaling and ion loading.

Hormesis: adaptation to a bounded stressor; too little may not adapt and too much damages.

Inflammation: coordinated immune and tissue response to threat or injury; adaptive when controlled and costly when chronic or misdirected.

Myelin: lipid-rich insulation around axons that increases speed and reliability of signaling.

Neurogenesis: production and maturation of new neurons.

Neuroprotection: preservation of cells or function against a defined threat.

Neurotrophin: signaling protein involved in neuronal survival, maintenance, and plasticity.

Nootropic: substance or intervention intended to improve a defined cognitive function; modern usage is broader than the word's original criteria.

Plasticity: nervous-system change produced by activity, experience, development, injury, or environment.

Receptor: protein that detects a ligand and changes cellular activity.

Salience: importance or priority assigned to an input.

Synapse: functional junction through which one cell influences another.

Synaptogenesis: creation of new synapses.

Therapeutic window: range between effective and unacceptably harmful exposure.

Tolerance: reduced response after repeated exposure.

Withdrawal: symptoms caused by removing or reducing an exposure after adaptation.

Spoiler: Appendix K — Source and Citation Standard

Appendix K — Source and Citation Standard​

This appendix is not a substitute for the citations attached to individual compound entries. It is the standard for recording and checking those sources. Use primary studies for compound-specific claims and authoritative reviews for orientation. Record the permanent identifier, exact formulation, population, dose, duration, outcomes, and funding.

• Standard neuroscience texts covering neuroanatomy, synapses, transmitters, plasticity, sleep, and behavior
• Standard pharmacology texts covering receptor theory, pharmacokinetics, interactions, toxicology, and clinical trial interpretation
• CONSORT guidance for randomized trials and PRISMA guidance for systematic reviews
• Cochrane methods for evidence synthesis and risk-of-bias assessment
• FDA, EMA, NIH, ClinicalTrials.gov, WHO, national poison centers, and official product labeling for regulatory and safety information
• Peer-reviewed literature indexed in PubMed and Crossref for permanent identifiers
• Pharmacopeial and accredited-laboratory standards for identity, purity, sterility, and endotoxin testing

Recommended bibliography record:

Author(s). Title. Journal or issuing body. Year;volume(issue):pages.
DOI/PMID/trial registration:
Study type and population:
Exact compound/formulation:
Primary outcome:
Main limitation:
Conflict/funding:
Guide chapter(s):

Vendor pages, forums, archived personal notes, and certificates of analysis belong in the source map, not in the evidence bibliography, unless the claim being documented is specifically what a vendor sold, said, or tested.

Spoiler: Appendix L — Index

Appendix L — Index​

• Acetylcholine and cholinergics: Chapters 5, 23
• Adaptogens and botanicals: Chapters 27–28, 30
• ADHD and executive function: Chapters 21–23, 57
• Anxiety and stress resilience: Chapters 16, 26–27, 60
• Brain anatomy and communication: Chapters 3–5
• Brain injury: Chapters 11, 19, 29, 65
• Brain metabolism and mitochondria: Chapters 6, 11, 17–18
• Catecholamines, dopamine, and motivation: Chapters 5, 20–21, 59
• Cognitive measurement: Chapters 39–41; Appendix E
• Dependence, tolerance, and withdrawal: Chapters 8, 26, 42, 45, 53, 55
• Diet and nutrients: Chapters 14–15
• Evidence evaluation: Chapters 37–38; Appendix I
• Exercise: Chapters 13, 63–64
• GABAergic compounds: Chapter 26
• Glutamate, NMDA, and AMPA: Chapters 5, 22
• Memory and learning: Chapters 7, 19, 22, 24, 58
• Metabolic compounds: Chapter 18
• Neuroprotection: Chapters 11, 19, 29, 64–65
• Neurotrophic compounds and peptides: Chapter 19
• N-of-1 trials: Chapters 46–56; Appendices F–H
• Product quality and sourcing: Chapters 43–44
• Psychedelics and plasticity: Chapters 25, 61, 66
• Racetams: Chapter 24
• Safety and toxicology: Chapters 42–45; Appendix G
• Sleep and sleep deprivation: Chapters 12, 20, 26, 62
• Wakefulness agents: Chapter 20

---

@Volpa #Volpamogs​

 

[cb.aesthetics]

mirin effort

 

[enchanted_elixir]

@youcouldbetheone @Deathninja328 @mangotimer @psltristan1 @Leo @Jgns @ghoulmania